bpc 157 case study BPC-157 and Healing Peptides: Hype or Hope? A Doctor's Comprehensive Perspective – MSK Doctor Zaid Matti The Human Lab Rats Injecting

Peptide legality varies by country and can change, so researchers should verify current regulations in their jurisdiction

[DOI] [PMC free article] [PubMed] [Google Scholar] 62.Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, Grabarevic Z, Stancic-Rokotov D, Pigac B, Hanzevacki M, Marovic A, Rucman R, Petek M, Zoricic I, Ziger T, Aralica G, Konjevoda P, Prkacin I, Gjurasin M, Miklic P, Artukovic B, Tisljar M, Bratulic M, Mise S, Rotkvic I

The TAS level was found to be significantly lower in the IR group compared to the control and BPC-applied groups ( p = 0.002, p = 0.034, respectively)

The standard regimen is 1 mg administered three times weekly for two weeks (or on alternate days for six doses if neurological symptoms are present), followed by maintenance doses every two to three months